Loyal

Loyal is a clinical-stage veterinary medicine company that develops drugs intended to extend the healthspan and lifespan of dogs.

Latest funding

$100M Series B+ · February 11, 2026

Latest round on record: Series A, March 2026, amount undisclosed.

Total raised: $167M across 3 sourced rounds

Website: loyal.com.

X: @loyalfordogs · 4,442 followers.

LinkedIn: loyalfordogs.

Category: Health and bio.

Sectors: Biotechnology, Pet, Pharmaceutical, Veterinary.

Stage: Series B+.

Based in: San Francisco, United States.

Total raised: $167M in 3 sourced rounds.

Last round: Mar 25, 2026 · 235 days ago.

Headcount: 51–100 employees.

On Recent Funding since: Sep 29, 2026.

Signals

X account@loyalfordogs · created Oct 14, 2020 (6 years old) · 4,442 followers

Website registeredJun 25, 1996 (30 years old)

About Loyal

It develops longevity drugs for dogs, including senior and large-breed dogs. Loyal makes money by selling pharmaceutical therapies for dogs.

TIMELINE · MONEY RAISED

@loyalfordogs·Raised $167M in 3 sourced rounds·1 signal before the first raise

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Date	Round	Amount	Lead	Source
Mar 25, 2026	Series A	undisclosed	—	fundraisingfox.com
Feb 11, 2026	Series B+	$100M	TThe Longevity Fund	businesswire.com
Feb 26, 2025	Series B+	$22M	CCollaborative Fund	finsmes.com
Mar 21, 2024	Series B+	$45M	BBain Capital Ventures	finsmes.com

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/loyal (get a free API key).